Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CFO Renee Gaeta sold 4,498 shares of the business's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $3.67, for a total value of $16,507.66. Following the sale, the chief financial officer owned 176,342 shares in the company, valued at approximately $647,175.14. The trade was a 2.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Outset Medical Stock Performance
OM stock traded down $0.23 during mid-day trading on Tuesday, reaching $3.16. 142,514 shares of the stock traded hands, compared to its average volume of 107,148. Outset Medical, Inc. has a 52-week low of $2.84 and a 52-week high of $6.49. The stock's fifty day moving average is $3.75 and its 200-day moving average is $4.09. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.86 and a quick ratio of 3.85.
Outset Medical (NASDAQ:OM - Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.01. Outset Medical had a negative net margin of 58.33% and a negative return on equity of 66.98%. The business had revenue of $33.60 million for the quarter, compared to the consensus estimate of $31.40 million. On average, research analysts expect that Outset Medical, Inc. will post -3.51 earnings per share for the current year.
Hedge Funds Weigh In On Outset Medical
Several institutional investors and hedge funds have recently bought and sold shares of OM. Marshall Wace LLP increased its holdings in shares of Outset Medical by 128.0% in the 3rd quarter. Marshall Wace LLP now owns 483,380 shares of the company's stock valued at $1,450,000 after purchasing an additional 271,387 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Outset Medical by 391.3% during the first quarter. Renaissance Technologies LLC now owns 222,075 shares of the company's stock worth $853,000 after purchasing an additional 176,870 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Outset Medical by 4.1% during the first quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company's stock worth $239,000 after purchasing an additional 2,435 shares during the period. Marquette Asset Management LLC acquired a new stake in shares of Outset Medical during the second quarter worth approximately $212,000. Finally, Sei Investments Co. grew its position in Outset Medical by 15.5% during the first quarter. Sei Investments Co. now owns 35,366 shares of the company's stock valued at $136,000 after purchasing an additional 4,738 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the stock. Wall Street Zen raised shares of Outset Medical from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Weiss Ratings cut Outset Medical from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, August 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $10.00.
Check Out Our Latest Report on Outset Medical
Outset Medical Company Profile
(
Get Free Report)
Outset Medical is a medical technology company that develops and sells products for hemodialysis, a treatment that filters waste and excess fluid from the blood. Its main product is the Tablo Hemodialysis System, an integrated dialysis platform designed for use in hospitals, clinics and home settings. Tablo combines dialysis equipment with water purification and a touchscreen interface, aiming to simplify treatment setup and operation. The system also supports access to treatment data through connected software tools.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Outset Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outset Medical wasn't on the list.
While Outset Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.